Instrument Inactif

Communiqués Probi AB

Actions

PROB

SE0001280355

Produits pharmaceutiques

Communiqués

03/02/25	Delisting of Probi	AQ
20/01/25	Notice of Extraordinary General Meeting in Probi AB (publ)	AQ
20/01/25	Probi applies for delisting and convenes an Extraordinary General Meeting	AQ
09/01/25	Probi postpones year-end report 2024	AQ
13/12/24	Statement from the independent bid committee of Probi in relation to the public takeover offer by Symrise	AQ
20/11/24	Probi's Board comments on Symrise's public takeover offer	AQ
13/11/24	Probi CFO departure	AQ
23/10/24	Probi Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024	AQ
22/10/24	Q3 2024: Tangible improvement in operations	AQ
17/10/24	Presentation of Probi's Q3 Report 2024	AQ
16/10/24	Probi partners with Global BHP BrainTrust and the FINGERS Brain Health Institute to counteract dementia	AQ
10/10/24	Nordic launch of Probi Sense - a unique dietary supplement for the mental capacity	AQ
24/09/24	New study strengthens Probi[ ][®]s L. plantarum HEAL9[®] strain in cognitive function	AQ
16/07/24	Q2 2024: Significant progress on strategic initiatives	AQ
11/07/24	Presentation of Probi's Q2 Report 2024	AQ
28/06/24	Probi® launches at Matas, Denmark's leading health retailer	AQ
27/06/24	Probi[®] strengthens the Gut-Brain offering with new study in older adults	AQ
23/05/24	Probi[®] strengthen its position in the Asia-Pacific region through strong customer collaborations	AQ
14/05/24	Probi® and ProViva celebrate 30 years of tasteful cooperation	AQ
07/05/24	Probi : acute;s Annual General Meeting 2024	PU
07/05/24	Probi's Annual General Meeting 2024	AQ
25/04/24	Probi partners with Bower to encourage increased recycling among consumers	AQ
23/04/24	Q1 2024: Steady Progress in a Transitional Year	AQ
18/04/24	Correction (date) Presentation of Probi's Q1 Report 2024	AQ
18/04/24	Presentation of Probi's Q1 Report 2024	AQ